Bryce Point Capital, LLC Nurix Therapeutics, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 28,564 shares of NRIX stock, worth $489,015. This represents 0.16% of its overall portfolio holdings.
Number of Shares
28,564Holding current value
$489,015% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.2MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$117 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$74.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$73.3 Million6.28% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$66.5 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$66.2 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $807M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...